Agenus Inc. (AGEN) on Focus After Raising In Today’s Session

February 15, 2018 - By Marry Poplack

Investors sentiment increased to 1.34 in Q3 2017. Its up 0.29, from 1.05 in 2017Q2. It increased, as 14 investors sold Agenus Inc. shares while 18 reduced holdings. 15 funds opened positions while 28 raised stakes. 36.96 million shares or 3.93% less from 38.48 million shares in 2017Q2 were reported.
Price T Rowe Assoc Md holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 30,500 shares. 32,691 are held by Zacks Invest. First Allied Advisory Services has 50,000 shares for 0.01% of their portfolio. Swiss National Bank has invested 0% in Agenus Inc. (NASDAQ:AGEN). Peddock Capital Advsr, Massachusetts-based fund reported 803 shares. Principal Fin, Iowa-based fund reported 11,284 shares. Geode Cap Mngmt Lc invested in 667,586 shares. Bancorp Of Montreal Can holds 0% or 500 shares. Vanguard Gp Inc reported 3.52 million shares. 214,826 are held by Morgan Stanley. Kistler holds 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN) for 200 shares. Walleye Trading Limited stated it has 32,000 shares. Alphamark Advsr Llc has invested 0% in Agenus Inc. (NASDAQ:AGEN). Bnp Paribas Arbitrage invested 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Northern Tru Corp reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN).

Since October 9, 2017, it had 0 insider purchases, and 5 selling transactions for $95,988 activity. Another trade for 6,546 shares valued at $22,651 was sold by Duncan Alex. Another trade for 3,712 shares valued at $12,846 was made by Baysal Ozer on Monday, October 9. Another trade for 5,610 shares valued at $19,418 was sold by KLASKIN CHRISTINE M. $28,921 worth of stock was sold by Valentine Karen on Monday, October 9.

The stock of Agenus Inc. (NASDAQ:AGEN) is a huge mover today! The stock increased 9.92% or $0.381 during the last trading session, reaching $4.221. About 1.58 million shares traded or 39.27% up from the average. Agenus Inc. (NASDAQ:AGEN) has declined 2.26% since February 15, 2017 and is downtrending. It has underperformed by 18.96% the S&P500.
The move comes after 8 months positive chart setup for the $430.39 million company. It was reported on Feb, 15 by We have $4.52 PT which if reached, will make NASDAQ:AGEN worth $30.13 million more.

Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on March, 8. They expect $-0.37 EPS, down 23.33 % or $0.07 from last year’s $-0.3 per share. After $-0.37 actual EPS reported by Agenus Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Agenus Inc. (NASDAQ:AGEN) Ratings Coverage

Among 5 analysts covering Agenus (NASDAQ:AGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Agenus had 10 analyst reports since July 27, 2015 according to SRatingsIntel. MLV maintained the stock with “Buy” rating in Monday, July 27 report. As per Tuesday, October 27, the company rating was downgraded by Maxim Group. The stock of Agenus Inc. (NASDAQ:AGEN) earned “Buy” rating by Jefferies on Thursday, August 3. The rating was maintained by Maxim Group on Thursday, October 27 with “Buy”. The company was downgraded on Friday, October 28 by H.C. Wainwright. Maxim Group upgraded the stock to “Buy” rating in Friday, March 11 report. The stock of Agenus Inc. (NASDAQ:AGEN) has “Buy” rating given on Wednesday, December 16 by Jefferies. The firm has “Buy” rating given on Monday, June 26 by Jefferies. The firm has “Buy” rating by Jefferies given on Friday, July 29. JMP Securities maintained it with “Market Outperform” rating and $15 target in Wednesday, March 9 report.

More recent Agenus Inc. (NASDAQ:AGEN) news were published by: which released: “The case for Agenus” on February 13, 2018. Also published the news titled: “Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty …” on January 22, 2018.‘s news article titled: “Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884 …” with publication date: January 22, 2018 was also an interesting one.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $430.39 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.